-葡萄糖共运输体-2抑制剂对体外血小板激活的常见和明显影响
Surasak Wichaiyo1, Rasika Khaeduang2, Supavit Taesakul2
1Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Centre of Biopharmaceutical Science for Healthy Ageing, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Biochemical pharmacology
|December 26, 2025
概括
像empagliflozin和dapagliflozin这样的-葡萄糖共运输体-2 (SGLT2) 抑制剂在纳米分子度下表现出抗血小板作用. 这些药物适度抑制血小板聚合并影响信号通路,在两者之间观察到一些明显的效应.
科学领域:
- 心血管药理学心血管药理学
- 血小板生物学 血小板生物学
- 内分泌学 在内分泌学.
背景情况:
- 已知-葡萄糖共运输体-2 (SGLT2) 抑制剂对心血管有好处.
- 以前的研究表明,SGLT2抑制剂在高微分子度下具有抗血小板活性.
- 临床相关的纳米分子度对血小板功能的影响在很大程度上仍未被探索.
研究的目的:
- 在纳米分子度下研究empagliflozin和dapagliflozin的抗血小板作用.
- 为了比较这些SGLT2抑制剂在体外对人类血小板功能的影响.
- 探索潜在的分子机制,这些机制是它们对血小板的影响的基础.
主要方法:
- 在体外测试中使用人类富血小板血 (PRP).
- 评估对对原和腺二酸盐 (ADP) 的反应中的血小板激活和聚合.
- 通过分子对接进行蛋白质酸化 (VASP),细胞因子分泌 (TNF-α),蛋白质表达 (eNOS) 和酶活性 (PKA) 的分析.
主要成果:
- 恩帕格利弗洛辛和达帕格利弗洛辛 (0.625μM) 显著抑制了原诱导的血小板聚合 (~20%).
- 作为对ADP的反应,SGLT2抑制剂增加了VASP酸化,这表明血小板抑制.
- 达帕格利弗洛辛,但不包括恩帕格利弗洛辛,增加了TNF-α分泌和eNOS表达;恩帕格利弗洛辛增强了PKA活性.
结论:
- 恩帕格利弗洛辛和达帕格利弗洛辛在纳米分子度下对血小板功能表现出共同而独特的作用.
- 在PKA活性,eNOS表达和TNF-α分泌中的差异可能解释不同的血小板活动.
- 这些发现有助于了解SGLT2抑制剂的心血管机制.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Secondary Active Transport
136.4K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.4K
Secondary Active Transport
9.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.2K
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K


